Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning

Neurobiology of Aging

Volumn 43, Issue , 2016, Pages 23-33

  Hassenstab, Jason ^a,b   Chasse, Rachel ^a   Grabow, Perri ^a,c   Benzinger, Tammie L S ^a,c   Fagan, Anne M ^a   Xiong, Chengjie ^a   Jasielec, Mateusz ^a   Grant, Elizabeth ^a   Morris, John C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF MISSOURI ST LOUIS   (United States)

Author keywords

Alzheimer's disease; Biomarkers; Cognition; Memory; Normative data; Preclinical disease

Indexed keywords

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; CAUCASIAN; CLINICAL DEMENTIA RATING; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DEPTH PERCEPTION; DISEASE CLASSIFICATION; EPISODIC MEMORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RACE DIFFERENCE; WECHSLER MEMORY SCALE; AGING; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; HIPPOCAMPUS; PATHOLOGY; PSYCHOLOGY;

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT; TAU PROTEIN;

AGED; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; COGNITION; COHORT STUDIES; FEMALE; HIPPOCAMPUS; HUMANS; MALE; NEUROIMAGING; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84963964149     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2016.03.014     Document Type: Article

References (64)

1. Agresti A. Categorical Data Analysis 2002, John Wiley & Sons, Hoboken, NJ. Second. ed.
2. 2014 Alzheimer's disease facts and figures. Alzheimers Dement 2014, 10:e47-e92. Alzheimer's Association.
3. Armitage S.G. An analysis of certain psychological tests used for the evaluation of brain injury. Psychol. Monogr. 1946, 60:i-48. 10.1037/h0093567.
4. Bateman R.J., Xiong C., Benzinger T.L.S., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., Holtzman D.M., Santacruz A., Buckles V., Oliver A., Moulder K., Aisen P.S., Ghetti B., Klunk W.E., McDade E., Martins R.N., Masters C.L., Mayeux R., Ringman J.M., Rossor M.N., Schofield P.R., Sperling R.A., Salloway S., Morris J.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 2012, 367:795-804. Dominantly Inherited Alzheimer Network.
5. Beach T.G., Monsell S.E., Phillips L.E., Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J. Neuropathol. Exp. Neurol. 2012, 71:266-273.
6. Benton A.L. The Revised Visual Retention Test: Clinical and Experimental Applications 1963, Psychological Corporation, New York.
7. Berg L., McKeel D.W., Miller J.P., Storandt M., Rubin E.H., Morris J.C., Baty J., Coats M., Norton J., Goate A.M. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol. 1998, 55:326.
8. Berg L., Miller J.P., Baty J., Rubin E.H., Morris J.C., Figiel G. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann. Neurol. 1992, 31:242-249.
9. Buckner R.L., Head D., Parker J., Fotenos A.F., Marcus D., Morris J.C., Snyder A.Z. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. NeuroImage 2004, 23:724-738.
10. Coats M., Morris J.C. Antecedent biomarkers of Alzheimer's disease: the adult children study. J. Geriatr. Psychiatry Neurol. 2005, 18:242-244.
11. De Santi S., Pirraglia E., Barr W., Babb J., Williams S., Rogers K., Glodzik L., Brys M., Mosconi L., Reisberg B., Ferris S., de Leon M.J. Robust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline. Neuropsychology 2008, 22:469-484.
12. Deary I.J., Corley J., Gow A.J., Harris S.E., Houlihan L.M., Marioni R.E., Penke L., Rafnsson S.B., Starr J.M. Age-associated cognitive decline. Br. Med. Bull. 2009, 92:135-152.
13. Desikan R.S., Ségonne F., Fischl B., Quinn B.T., Dickerson B.C., Blacker D., Buckner R.L., Dale A.M., Maguire R.P., Hyman B.T., Albert M.S., Killiany R.J. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage 2006, 31:968-980.
14. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/β-Amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 2007, 64:343-349.
15. Fischl B., Salat D.H., Busa E., Albert M., Dieterich M., Haselgrove C., van der Kouwe A., Killiany R., Kennedy D., Klaveness S., Montillo A., Makris N., Rosen B., Dale A.M. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33:341-355.
16. Foltynie T. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2003, 127:550-560.
17. Goodglass H., Kaplan E. Boston Naming test scoring booklet, Lea & Febiger, Philadelphia 1983.
18. Grober E., Buschke H., Crystal H., Bang S., Dresner R. Screening for dementia by memory testing. Neurology 1988, 38:900-903.
19. Grober E., Hall C.B., Lipton R.B., Zonderman A.B., Resnick S.M., Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J. Int. Neuropsychol. Soc. 2008, 14:266-278.
20. Grober E., Lipton R.B., Katz M., Sliwinski M. Demographic influences on free and cued selective reminding performance in older persons. J. Clin. Exp. Neuropsychol. 1998, 20:221-226.
21. Grober E., Sanders A.E., Hall C., Lipton R.B. Free and cued selective reminding identifies very mild dementia in primary care. Alzheimer Dis. Assoc. Disord. 2010, 24:284-290.
22. Hayden K.M., Reed B.R., Manly J.J., Tommet D., Pietrzak R.H., Chelune G.J., Yang F.M., Revell A.J., Bennett D.A., Jones R.N. Cognitive decline in the elderly: an analysis of population heterogeneity. Age and Ageing 2011, 40:684-689.
23. Holtzer R., Goldin Y., Zimmerman M., Katz M., Buschke H., Lipton R.B. Robust norms for selected neuropsychological tests in older adults. Arch. Clin. Neuropsychol. 2008, 23:531-541.
24. Howieson D.B., Carlson N.E., Moore M.M., Wasserman D., Abendroth C.D., Payne-Murphy J., Kaye J.A. Trajectory of mild cognitive impairment onset. J. Int. Neuropsychol. Soc. 2008, 14:192-198.
25. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., Donohue M.C., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
26. Jack C.R., Knopman D.S., Weigand S.D., Wiste H.J., Vemuri P., Lowe V., Kantarci K., Gunter J.L., Senjem M.L., Ivnik R.J., Roberts R.O., Rocca W.A., Boeve B.F., Petersen R.C. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann. Neurol. 2012, 71:765-775.
27. Jack C.R., Twomey C.K., Zinsmeister A.R., Sharbrough F.W., Petersen R.C., Cascino G.D. Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology 1989, 172:549-554.
28. Jak A.J., Bondi M.W., Delano-Wood L., Wierenga C., Corey-Bloom J., Salmon D.P., Delis D.C. Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am. J. Geriatr. Psychiatry 2009, 17:368-375.
29. Johnson D.K., Storandt M., Morris J.C., Galvin J.E. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch. Neurol. 2009, 66:1254-1259.
30. Johnson D.K., Storandt M., Morris J.C., Langford Z.D., Galvin J.E. Cognitive profiles in dementia: Alzheimer disease vs healthy brain aging. Neurology 2008, 71:1783-1789.
31. Knopman D.S., Jack C.R., Wiste H.J., Weigand S.D., Vemuri P., Lowe V., Kantarci K., Gunter J.L., Senjem M.L., Ivnik R.J., Roberts R.O., Boeve B.F., Petersen R.C. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012, 78:1576-1582.
32. Luo L., Craik F.I. Aging and memory: a cognitive approach. Can. J. Psychiatry/La Revue canadienne de Psychiatrie 2008, 53:346-353.
33. McNemar Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 1947, 12:153-157.
34. Mintun M., Larossa G., Sheline Y., Dence C., Lee S., Mach R., Klunk W., Mathis C., DeKosky S., Morris J. [11C] PIB in a nondemented population Potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
35. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
36. Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H., Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch. Neurol. 2001, 58:397-405.
37. Morris J.C., Weintraub S., Chui H.C., Cummings J., Decarli C., Ferris S., Foster N.L., Galasko D., Graff-Radford N., Peskind E.R., Beekly D., Ramos E.M., Kukull W.A. The Uniform data set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease Centers. Alzheimer Dis. Assoc. Disord. 2006, 20:210-216.
38. Oh H., Madison C., Haight T.J., Markley C., Jagust W.J. Effects of age and β-amyloid on cognitive changes in normal elderly people. Neurobiol. Aging 2012, 33:2746-2755.
39. Pedraza O., Lucas J.A., Smith G.E., Petersen R.C., Graff-Radford N.R., Ivnik R.J. Robust and enorms for the Dementia Rating Scale. Arch. Clin. Neuropsychol. 2010, 25:347-358.
40. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
41. Pizzie R., Hindman H., Roe C.M., Head D., Grant E., Morris J.C., Hassenstab J.J. Physical activity and cognitive trajectories in cognitively normal adults: the adult children study. Alzheimer Dis. Assoc. Disord. 2014, 28:50-57.
42. Pizzie R., Hindman H., Roe C.M., Head D., Grant E., Morris J.C., Hassenstab J.J. Physical activity and cognitive trajectories in cognitively normal adults: the adult children study. Alzheimer Dis. Assoc. Disord 2014, 28:50-57.
43. Price J.L., McKeel D.W., Buckles V.D., Roe C.M., Xiong C., Grundman M., Hansen L.A., Petersen R.C., Parisi J.E., Dickson D.W., Smith C.D., Davis D.G., Schmitt F.A., Markesbery W.R., Kaye J., Kurlan R., Hulette C., Kurland B.F., Higdon R., Kukull W., Morris J.C. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 2009, 30:1026-1036.
44. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 1999, 45:358-368.
45. Ritchie L.J., Frerichs R.J., Tuokko H. Effective normative samples for the detection of cognitive impairment in older adults. Clin. Neuropsychol. 2007, 21:863-874.
46. Rodrigue K.M., Kennedy K.M., Devous M.D., Rieck J.R., Hebrank A.C., Diaz-Arrastia R., Mathews D., Park D.C. β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 2012, 78:387-395.
47. Roe C.M., Fagan A.M., Grant E.A., Hassenstab J., Moulder K.L., Dreyfus D.M., Sutphen C.L., Benzinger T.L., Mintun M.A., Holtzman D.M. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013, 80:1784-1791.
48. Salthouse T.A. Aging and measures of processing speed. Biol. Psychol. 2000, 54:35-54.
49. Saxton J., Lopez O.L., Ratcliff G., Dulberg C., Fried L.P., Carlson M.C., Newman A.B., Kuller L. Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology 2004, 63:2341-2347.
50. Sliwinski M., Lipton R.B., Buschke H., Stewart W. The effects of preclinical dementia on estimates of normal cognitive functioning in aging. J. Gerontol. B Psychol. Sci. Soc. Sci. 1996, 51:P217-P225.
51. Sliwinski M.J., Hofer S.M., Hall C., Buschke H., Lipton R.B. Modeling memory decline in older adults: the importance of preclinical dementia, Attrition, and Chronological age. Psychol. Aging 2003, 18:658-671.
52. Small S.A. Age-related memory decline: current concepts and future directions. Arch. Neurol. 2001, 58:360-364.
53. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
54. Storandt M., Morris J.C. Ascertainment bias in the clinical diagnosis of Alzheimer disease. Arch. Neurol. 2010, 67:1364-1369.
55. Thurstone T.G., Thurstone L.L. SRA Primary Mental Abilities, Science Research Associates, Chicago 1948.
56. Villemagne V.L., Burnham S., Bourgeat P., Brown B. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013, 12:357-367.
57. Vos S.J., Xiong C., Visser P.J., Jasielec M.S., Hassenstab J., Grant E.A., Cairns N.J., Morris J.C., Holtzman D.M., Fagan A.M. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013, 12:957-965.
58. Wechsler D. WMS-r: Wechsler Memory Scale-revised: Manual, Psychological Corporation, New York 1987.
59. Wechsler D. Wechsler: Wechsler Adult Intelligence Scale-revised, Psychological Corporation, New York 1981.
60. Weintraub S., Salmon D., Mercaldo N., Ferris S., Graff-Radford N.R., Chui H., Cummings J., Decarli C., Foster N.L., Galasko D., Peskind E., Dietrich W., Beekly D.L., Kukull W.A., Morris J.C. The Alzheimer's disease Centers' Uniform data set (UDS): the neuropsychologic test battery. Alzheimer Dis. Assoc. Disord. 2009, 23:91-101.
61. Wilson R.S., Leurgans S.E., Boyle P.A., Schneider J.A., Bennett D.A. Neurodegenerative basis of age-related cognitive decline. Neurology 2010, 75:1070-1078.
62. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., Nordberg A., Backman L., Albert M., Almkvist O., Arai H., Basun H., Blennow K., de Leon M., DeCarli C., Erkinjuntti T., Giacobini E., Graff C., Hardy J., Jack C., Jorm A., Ritchie K., van Duijn C., Visser P., Petersen R.C. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International working group on mild cognitive impairment. J. Intern. Med. 2004, 256:240-246.
63. Yu L., Boyle P.A., Leurgans S., Schneider J.A., Bennett D.A. Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. Neurobiology Aging 2014, 35:819-826.
64. Yu L., Boyle P.A., Segawa E., Leurgans S., Schneider J.A., Wilson R.S., Bennett D.A. Residual decline in cognition after adjustment for common neuropathologic conditions. Neuropsychology 2014, 29:335-343.